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Abstract 
Objective: To evaluate the effects on ALT normalization in the first month by SOFOS/RIB therapy versus 
SOFOS/DAC therapy in HCV infected individuals in Pakistan. 
Study Design:  Cross-sectional comparative study. 
Material and Methods: A cross-sectional analysis was performed in a total of 200 Hepatitis C infected patients, 
sex, history of diabetes mellitus, prior interferon therapy, decrease in hemoglobin >2 gm/dl in 1st month and rise 
in serum bilirubin in 1st month was the qualitative variables and the quantitative variables were age, weight, 
baseline hemoglobin, baseline bilirubin at week 4 of treatment. The statistical relation of the mentioned variables 
was checked using SPSS version 15 on the basis of data collected. 
Results: Out of total 200 patients, 47% (94) were males, 53% (106) were females, 28% (56) patients were diabetic & 
44.5% (89) patients had history of prior interferon therapy, 28.5% (57) patients were having low hemoglobin levels 
before starting above mentioned treatment. Both the groups completed the treatments A & B for 24 &12 weeks 
respectively & collected data showed the superiority of treatment B to treatment A as no decrease in hemoglobin 
(p=0.000), & no rise in serum bilirubin(p=0.000) during 1st month of treatment while serum bilirubin was 93 % in 
treatment B and 73 % in treatment A. 
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Conclusion: The results concluded that treatment B (Sofosbuvir / Daclatasvir for 12 weeks) is superior anti-
hepatitis C therapy as compared to the treatment A (Sofosbuvir / Ribavirin for 24 weeks) in order to achieve ALT 
normalization in the first month of therapy in Pakistani population. Ribavirin should be avoided to prevent 
hemolytic anemia as well.  
Keywords: Hepatitis C, Alkaline Phosphatase. 
 
 
Introduction 
 
The majority of individuals with acute hepatitis C 
virus (HCV) infection progress to chronic infection 1,2, 
and are at increased risk of liver fibrosis progression.3, 
4 Several studies have demonstrated that while 
elevation of alanine aminotransferase (ALT) is an 
important predictor of the development and 
progression of liver fibrosis in chronic HCV infection, 
HCV RNA levels have limited role in this regard.4,5 
This supports a hypothesis suggesting a more 
important role of intra-hepatic inflammation in the 
development and progression of liver fibrosis than 
direct HCV cytotoxicity in HCV infection.  This 
triggered the author to compare the “effects on ALT 
normalization in the first month by Sofos/RIB therapy 
versus Sofos/DAC therapy in HCV infected 
individuals” in order to come to know that if any 
discrepancy is found in both oral treatment lines, it 
could be noted. 
In certain areas of Pakistan Hepatitis C Virus (HCV) is 
ruinous to the system of human health; where about 3-
13% of  population6 is infected with Hepatitis C viral 
infection in the country. Decompensated liver cirrhosis 
together with hepatocellular carcinoma is the most 
common cause of death associated with chronic HCV 
infection.7  
The only known nucleoside analogue is Sofosbuvir 
that binds directly to the active site of 
polymerase/NS5B8 of the hepatitis C virus, so it is 
highly effective against all genotypes and possesses a 
high barrier to resistance. While Daclatasvir is an 
NS5A inhibitor 9, which is also effective against all 
genotypes. However, it possesses a low barrier to 
resistance. So, adequate combination partners are 
required to overcome this resistance.   
The result of the antiviral therapy is estimated by 
sensitive HCV-PCR testing with a lower limit of 
detection < 15 IU / ml.10 Undetectable HCV-RNA at 
the end of the therapy, and at 12/24 weeks after the 
completion of the therapy define End Treatment 
Response (ETR) and Sustained Virological Response 
(SVR).11 Internationally, both SVR 12 and SVR 24 have 
been accepted as the endpoints for HCV therapy.12 
Free availability of the above-mentioned drug 
combination antiviral therapy at some government 
hospitals plus a very low market rate i.e. at almost 
Rupees 2000/- made the study cost-effective. The 
primary goal of chronic HCV infection treatment is to 
achieve sustained viral response (SVR), characterized 
by the complete disappearance of the hepatitis C virus 
from a patient’s body. SVR is associated with 
decreased liver disease mortality rate together with 
all-cause mortality rate.13 
 
Patients and Methods 
 
This was a cross-sectional comparative study carried 
out at, Al Rauf Medical and Surgical Hospital 
Sargodha Region from July to December 2018.  A total 
of 200 patients of chronic hepatitis C aged 18 years and 
above with positive HCV-RNA were enrolled. The 
exclusion criteria were patients with decompensated 
liver disease and child pug score >12, pregnancy, HIV 
and/or HBV co-infection and renal dysfunction with 
Creatinine clearance <50 mL /minute. 
The enrolled patients were divided into two groups, 
each consisting of 100 patients. First group patients 
were treated with a combination of Sofosbuvir and 
ribavirin for 24 weeks. SOFOSBUVIR was given in a 
dose of 400mg daily, while ribavirin was given 1000 
mg in divided doses for patients weighing less than 70 
kg and 1200 mg for those weighing 70 kg and above 
[14]. Second group patients were treated with a 
combination of Sofosbuvir and Daclatasvir for 12 
weeks. Sofosbuvir was given in a dose of 400mg daily, 
while Daclatasvir was given in a dose of 60mg daily. 
The first group was named group A while second as 
group B. Bio-data including age, sex, weight, history of 
diabetes mellitus, prior interferon therapy,   baseline 
hemoglobin (Hb), and baseline bilirubin were noted. 
The change in baseline biochemical and hematological 
parameters was checked at 4 weeks of therapy. The 
serum HCV-RNA testing was performed at the end of 
treatment and 12 weeks after the end of treatment to 
see for ETR and SVR-12 respectively. During data 
interpretation, the anemia was defined as a 
hemoglobin (Hb) level of less than 13.5 g/dl for males 
and less than 12g/dl for females [15]. 
The descriptive analysis of the collected data was done 
using SPSS version 15. Gender, history of diabetes 
mellitus, prior interferon therapy,  decrease in 
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Hb>2g/dl in 1st month, and rise in serum bilirubin in 
1st month were qualitative variables, while age, 
weight, baseline hemoglobin (Hb), and baseline 
bilirubin, Hb at 4 weeks of therapy,  4 weeks of 
therapy and serum bilirubin at 4 weeks of therapy 
were quantitative variables. Investigational data was 
interpreted in negative or positive values. For 
quantitative variables, means and standard deviations 
were calculated and for qualitative variables, 
frequencies and percentages were computed. A Chi-
square test was applied to find an association of 
factors at a 5% level of significance. The odds ratio 
with a 95% confidence interval (CI) was also calculated 
for each association [15]. 
 
Result 
 
There were a total of 200 patients with a mean age of 
44.24 ± 11.20years. Their weight ranged from 38 to 113 
kg with a mean value of 73.35 + 13.00 Kg. The mean 
values of baseline Hb, and bilirubin were 13.04 + 
1.68g/dl and 0.98 +0.66 (Table1). 
Out of a total of 200 patients, 47% (94) were males and 
53% (106) were females. 28% (56) patients were 
diabetic and 44.5% (89) patients had a history of (H/O) 
prior to interferon therapy.  28.5% (57) patients were 
anemic before starting antiviral therapy (Table 2). 
100 patients in each of groups A and B completed 
Sofosbuvir/ribavirin therapy and 
Sofosbuvir/daclatasvir therapy respectively. The ETR  
was achieved in 95% and 97 % in groups A and B 
respectively. The SVR was 93% in group B compared 
to 73% in group A. 
The superiority of group B therapy over group A was 
observed in statistical figures. No decline in Hb> 
2g/dl during the first month of therapy (p=0.000), and 
no rise in serum bilirubin during the first month of 
therapy (p=0.000) was significantly seen in the group B 
patients as compared to group A patients. The 
decrease in Hb> 2g/dl during the first month of 
therapy was found in 50% of group A patients while 
only 9% of group B suffered a decrease in Hb> 2g/dl 
during the first month of therapy.  
The serum bilirubin became elevated than normal 
value during the first month of therapy in 46% of 
group A and only 7 % of group B patients. And finally, 
ALT normalization during the first month of therapy 
was seen in 51% of group A and 90% of group B 
patients while 49 % individuals of group A and just 
10% of group B failed to achieve the normal ALT 
levels during the first month of therapy (Table 3). 
 
Table 1: Descriptive statistics of quantitative 
variables (n = 200). 
Quantitative Variables/ 
categories 
Minim
um 
Maxi
mum 
Mean + SD 
Age (Years) 19 75 44.24+11.20 
Weight (Kg) 38 113 73.35+13.00 
Baseline Hb (g/dl) 8.9 17.3 13.04+1.68 
Baseline ALT (IU/L) 12 623 82.02 +66.27 
Baseline Bilirubin (mg/dl) 0.2 4.6 0.98 +0.66 
Hb at week 4 (g/dl) 6.5 16 11.77+ 1.79 
ALT at week 4 (IU/L) 11 122 26.56+15.58 
Serum Bilirubin at week 4 
(mg/dl) 
0.1 5.5 0.92+ 0.59 
WBCs= White Blood Cells; ALT = Alanine 
Aminotransferase; INR= International Normalized Ratio 
 
Table 2: Qualitative variables (n = 200) 
Variables/
Categories 
Treatment offered Total  
SOV+RVB SOV + DAC 
Gender: 
Male  48 (48%) 46 (46%) 94 (47%) 
Female 52 (52%) 54 (54%) 106 (53%) 
H/O Diabetes mellitus 
Yes 28 (28%) 28 (28%) 56 (28%) 
No 72 (72%) 72 (72%) 144 (72%) 
H/O Prior interferon therapy 
Yes 45 (45%) 44 (44%) 89 (44.5%) 
No 55 (55%) 56 (56%) 111 (55.5%) 
ALT normalization during the first month of therapy 
Yes 51 (51%) 90 (90%) 141 (70.5%) 
No 49 (49%) 10 (10%) 59 (29.5%) 
Baseline Hb 
Normal 66 (66%) 77 (77%) 143 (71.5%) 
Low 34(34%) 23 (23%) 57(28.5%) 
 
Table 3: Comparison of response to therapy as well 
as hematological and biochemical parameters (n = 
200). 
Predictors/Cate
gories 
Treatment offered  Total  p-value Odd ratio 
with 95% 
Confidence 
interval 
SOV+R
VB 
(n=100) 
SOV + 
DAC 
(n=100) 
ALT normalization during first month of therapy: 
Yes 10 (20%)    45 
(90%) 
90 0.799 1.000 (0.271-
3.694) 
No 40 (80%) 5 (10%) 10 
End Treatment Response (ETR): 
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Achieved 95 
(49.5%) 
97 
(50.5%) 
192 0.721 1.702 (0.396-
7.321) 
Not-achieved 5 (62.5%) 3 (37.5%) 8 
Sustained Virological Response (SVR) 12: 
Achieved 73 (44%) 93 (56%) 166 0.000 4.914 (2.026-
11.918) Not-achieved 27 (79%) 7 (21%) 34 
Decrease in Hb> 2g/dl during first month of therapy: 
Yes 50 
(84.7%) 
9 (15.3%) 59                    
                   
         
0.000 
0.099 (0.045-
0.218) 
No 50 
(35.5%) 
91 
(64.5%) 
141 
Rise in Serum Bilirubin during first month of therapy: 
Yes 46 
(86.8%) 
7 (13.2%) 53 0.000 0.088 (0.037-
0.209) 
No 54 
(36.7%) 
93 
(63.3%) 
147 
 
Discussion 
 
Sofosbuvir based direct-acting antiviral therapy 
against HCV is a miracle. The responses to these 
therapies are excellent. In VALENCE trial 14 on 
Sofosbuvir/ Ribavirin for 24 weeks duration, ETR was 
> 90%, while SVR 12 in treatment-experienced 
cirrhotic patients was only 62%. Similarly, ALLY-3 
trial 15 on Sofosbuvir/ Daclatasvir therapy showed 
both ETR and SVR 12 above 90%. The same 
combination is now recommended in all HCV 
genotypes.5 
In our study, serum ALT Normalization in the first 
month after starting the antiviral therapy was not 
achieved well with Sofosbuvir/ Ribavirin therapy (i.e. 
only 20 % in comparison to 90%). This suggests the 
more potent Sofosbuvir/ Daclatasvir therapy of 12 
weeks duration in our population in achieving serum 
ALT Normalization in the first month after starting the 
antiviral therapy in contrast to group A patients. So 
ALT normalization, during the first month of therapy 
was seen more in patients treated with Sofosbuvir/ 
Daclatasvir as compared to Sofosbuvir / Ribavirin 
therapy (90% versus 51%). 
In addition to that many side effects are noted in the 
patients treated with Ribavirin like hemolysis, anemia, 
insomnia, pruritis, anxiety, teratogenicity dry cough 
and hair loss.15 In the current study, only two 
parameters were compared in two groups of HCV 
infected patients. The patients receiving the treatment 
with Sofosbuvir/ Ribavirin suffered a decrease in Hb> 
2 g/dl during the first month of therapy more 
commonly than patients receiving Sofosbuvir/ 
Daclatasvir therapy (50% versus 9% only) in addition 
to that. Similarly, the Sofosbuvir / Ribavirin group 
had a more rise in serum bilirubin during the first 
month of therapy (46% versus 7%). Hence a large 
number of patients suffered hemolytic anemia due to 
ribavirin in the group who received Sofosbuvir/ 
Ribavirin for 24 weeks. This whole scenario was 
suggestive that Sofosbuvir/ Daclatasvir therapy was 
more efficacious and had fewer side effects in our 
population. However, larger studies are required to 
validate these findings. 
 
Conclusion 
 
In conclusion, this study demonstrated that 
Sofosbuvir/ Daclatasvir for 12 weeks is a better 
antiviral therapy for hepatitis C regarding rapid end of 
injury to hepatocytes due to hepatitis C infection and 
letting back the ALT levels to its normal levels (hence 
preventing further decompensating of this culprit 
disease) as rapid as even first month of starting of 
antiviral therapy than Sofosbuvir / Ribavirin for 24 
weeks in our population. In addition, hemolytic 
anemia is also a troublesome and serious side effect in 
half of the patients receiving ribavirin.  
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